Table 1.
Selection of finished studies using targeted therapy approaches in malignant pleural mesothelioma (MPM). The mutational rate in MPM was taken from the cosmic database. Data on expression were taken from indicated references.
| Target | Drug | Study | Year of Completion | Status | # Patients | Results | Marker | Mutational Rate in MPM | Expression in MPM |
|---|---|---|---|---|---|---|---|---|---|
| mTor | Everolimus | NCT00770120 | 2014 | completed | 61 | primary endpoint not reached | NF2 (Merlin) | 17% (105/629) | 4% [31]–8% [32] negative |
| NCT01024946 | 2012 | completed | 11 | none published | |||||
| FAK | Defactinib | NCT01870609 | 2016 | terminated | 344 | lack of efficiency | |||
| ALK1 | PF-03446962 | NCT01486368 | 2015 | completed | 17 | primary endpoint not reached | ALK | 0% (1/343) | 0% [33]–20% [34] positive |
| EGFR | Erlotinib | NCT00039182 | 2007 | completed | 55 | primary endpoints not reached | EGFR | 1% (8/652) | 15% [25], 50% [26], 75% [28] high |
| Cetuximab | NCT00996567 | 2015 | completed | 22 | primary endpoint not reached | ||||
| c-Met | Tivantinib | NCT01861301 | 2015 | terminated | 18 | lack of efficiency | MET | 1% (3/448) | 17% [35]–40% [36] high |
Background color highlights groups of studies that employed the same marker for patient stratification.